BRIEF published on 01/27/2025 at 22:20, 1 year 6 months ago Theralase's Interim Clinical Data to be Highlighted at 2025 AUA Annual Meeting Clinical Data Theralase Bladder Cancer Light-activated Therapy Urological Innovations
PRESS RELEASE published on 01/27/2025 at 22:15, 1 year 6 months ago Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting Theralase announces interim clinical data presentation at AUA Annual Meeting, showcasing promising results of light-activated Ruvidar™ in treating BCG-Unresponsive NMIBC CIS Theralase Bladder Cancer Interim Clinical Data Light-activated Ruvidar AUA Annual Meeting
BRIEF published on 12/09/2024 at 14:10, 1 year 8 months ago Theralase Expands Clinical Study Sites for Bladder Cancer Treatment in the U.S. Cancer Research Bladder Cancer Treatment Theralase Expansion Clinical Study Sites Ruvidar Activation
BRIEF published on 12/09/2024 at 14:10, 1 year 8 months ago Theralase élargit ses sites d'études cliniques pour le traitement du cancer de la vessie aux États-Unis Recherche Sur Le Cancer Expansion De La Théralase Traitement Du Cancer De La Vessie Sites D'études Cliniques Activation De Ruvidar
PRESS RELEASE published on 12/09/2024 at 14:05, 1 year 8 months ago Theralase(R) Launches Three New Clinical Study Sites in USA Theralase® launches new US Clinical Study Sites for bladder cancer treatment. Principal Investigators announced. Positive clinical data presented Clinical Data Theralase® Bladder Cancer US Clinical Study Sites
BRIEF published on 12/05/2024 at 13:05, 1 year 8 months ago Theralase Technologies Expands Bladder Cancer Study in Canada Canada Expansion Clinical Study Bladder Cancer Ruvidar Theralase Technologies
BRIEF published on 12/05/2024 at 13:05, 1 year 8 months ago Theralase Technologies étend son étude sur le cancer de la vessie au Canada Étude Clinique Cancer De La Vessie Ruvidar Technologies Théralase Expansion Au Canada
PRESS RELEASE published on 12/05/2024 at 13:00, 1 year 8 months ago Theralase(R) Launches New Clinical Study Site in Canada St. Joseph's Healthcare Hamilton joins Theralase®'s clinical investigation for bladder cancer treatment. Theralase® develops light-activated Ruvidar™ drug for BCG-Unresponsive NMIBC CIS patients Theralase® Bladder Cancer BCG-Unresponsive NMIBC CIS RuvidarTM Clinical Study Site
BRIEF published on 11/27/2024 at 23:10, 1 year 8 months ago Theralase publie son aperçu financier du troisième trimestre 2024 Placements Privés Dépenses De Recherche Et Développement Aperçu Financier De Theralase Chiffre D'affaires Et Marges Résultats De L'étude II
BRIEF published on 11/27/2024 at 23:10, 1 year 8 months ago Theralase Releases 3Q2024 Financial Overview Private Placements R&D Expenses Theralase Financial Overview Revenue And Margins Study II Results
Published on 08/14/2026 at 13:30, 29 minutes ago Digi Power X Reports Second Quarter 2026 Financial Results and Provides Operational Update and 2027 Outlook
Published on 08/14/2026 at 13:15, 44 minutes ago Mako Mining Reports Q2 2026 Financial Results, Including Adjusted EBITDA(1) of US$31.7 Million and EPS of US$0.16/Share
Published on 08/14/2026 at 13:10, 49 minutes ago SouthGobi Announces Second Quarter 2026 Unaudited Financial and Operating Results
Published on 08/14/2026 at 09:01, 4 hours 58 minutes ago Apex Announces Filing of Final Base Shelf Prospectus
Published on 08/14/2026 at 08:00, 5 hours 59 minutes ago Touchstone Exploration Announces Second Quarter 2026 Results and Operational Update
Published on 08/14/2026 at 13:31, 27 minutes ago Diginex Limited Announces Extraordinary General Meeting to Approve Proposed Acquisition of Resulticks
Published on 08/14/2026 at 13:20, 38 minutes ago Nagarro Management Board and Supervisory Board recommend the acceptance of the voluntary public takeover offer by Persistent
Published on 08/14/2026 at 12:30, 1 hour 28 minutes ago Diginex and Resulticks Sign Amended Definitive Agreement to Create a Global AI-Powered Group Spanning Customer Engagement and Trusted Sustainability Data
Published on 08/14/2026 at 12:08, 1 hour 50 minutes ago Nagarro Management Board and Supervisory Board recommend the acceptance of the voluntary public takeover offer by Persistent
Published on 08/14/2026 at 12:05, 1 hour 53 minutes ago THE GALLIPOLI CAMPAIGN REVITALIZED IN THE DIGITAL REALM
Published on 08/13/2026 at 18:00, 19 hours 59 minutes ago Chiffre d’affaires du 1er trimestre 2026-27 : 14,4 M€
Published on 08/11/2026 at 17:45, 2 days 20 hours ago DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 2 days 20 hours ago Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 3 days 19 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 3 days 19 hours ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
